Lemonade Price Target Lifted to $49 at Morgan Stanley
Morgan Stanley raised its price target for Lemonade, Inc. (NYSE:LMND) to $49 from $45 on November 10, 2025. The firm maintained its Underweight rating on the technology-driven insurance company. The stock reacted positively, trading up 5.13%, or $3.85, to $78.87 for the day.
Despite the cautious analyst rating, Lemonade's stock has experienced significant growth, surging 214% over the past year. On November 10, the stock traded between a low of $75.52 and a high of $80.12. The company's market capitalization currently stands at approximately $5.77 billion, with a daily trading volume of 2,800,647 shares.
The company is reportedly moving closer to profitability on an adjusted EBITDA basis, following a strong third quarter that boosted market sentiment. However, a significant portion of analysts remain skeptical, with 42% of those covering the stock recommending to sell.
Lemonade operates as an insurance carrier powered by artificial intelligence and offers products like renters, homeowners, and pet insurance. The company utilizes digital tools and chatbots to streamline customer onboarding and claims processing. More information is available about Lemonade's financial health and for its investor profile.
Lemonade, Inc. (LMND) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.